Table 2 Characteristics of eligible RCTs
Category | Mainland China | United States | ||||
|---|---|---|---|---|---|---|
Non-redundant | Redundant | Total | Non-redundant | |||
Partially redundant | Entirely redundant | All redundant | ||||
No. of RCTs (%) | ||||||
 Total | 208 (21.2) | 144 (14.6) | 631 (64.2) | 775 (78.8) | 983 (100.0) | 5 (100.0) |
 Reperfusion | 147 (28.7) | 72 (14.0) | 294 (57.3) | 366 (71.3) | 513 (100.0) | 3 (100.0) |
 P2Y12 receptor inhibitors | 33 (11.8) | 41 (14.6) | 206 (73.6) | 247 (88.2) | 280 (100.0) | 0 (0.0) |
 Statins | 13 (26.5) | 7 (14.3) | 29 (59.2) | 36 (73.5) | 49 (100.0) | 2 (100.0) |
 Anticoagulants | 15 (10.6) | 24 (17.0) | 102 (72.3) | 126 (89.4) | 141 (100.0) | 0 (0.0) |
No. of patients recruited (%) | ||||||
 Total | 9094 (20.2) | 7389 (16.4) | 28,541 (63.4) | 35,930 (79.8) | 45,024 (100.0) | 284 (100.0) |
 Reperfusion | 6082 (27.0) | 3635 (16.1) | 12,827 (56.9) | 16,462 (73.0) | 22,544 (100.0) | 120 (100.0) |
 P2Y12 receptor inhibitors | 1891 (14.1) | 2031 (15.1) | 9489 (70.8) | 11,520 (85.9) | 13,411 (100.0) | 0 (0.0) |
 Statins | 583 (25.1) | 385 (16.6) | 1352 (58.3) | 1737 (74.9) | 2320 (100.0) | 164 (100.0) |
 Anticoagulants | 538 (8.0) | 1338 (19.8) | 4873 (72.2) | 6211 (92.0) | 6749 (100.0) | 0 (0.0) |
Ethics committee approval | ||||||
 Reported | 1 (0.5) | 2 (1.4) | 119 (18.9) | 121 (15.6) | 122 (12.4) | 3 (60.0) |
 Not reported | 207 (99.5) | 142 (98.6) | 509 (80.7) | 651 (84.0) | 858 (87.3) | 2 (40.0) |
Funding sources | ||||||
 Government | 3 (1.4) | 0 (0.0) | 14 (2.2) | 14 (1.8) | 17 (1.7) | 1 (20.0) |
 Industry | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (40.0) |
 Other | 1 (0.5) | 0 (0.0) | 5 (0.8) | 5 (0.6) | 6 (0.6) | 0 (0.0) |
 Not reported | 204 (98.1) | 144 (100.0) | 612 (97.0) | 756 (97.5) | 960 (97.7) | 2 (40.0) |
MACE as an outcome | ||||||
 Reported | 151 (72.6) | 93 (64.6) | 297 (47.1) | 390 (50.3) | 541 (55.0) | 4 (80.0) |
 Not reported | 57 (27.4) | 51 (35.4) | 334 (52.9) | 385 (49.7) | 442 (45.0) | 1 (20.0) |